Literature DB >> 13129593

Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury.

Adem Aydin1, Kursad Genç, Mustafa Akhisaroglu, Kutsal Yorukoglu, Necati Gokmen, Erdem Gonullu.   

Abstract

Hypoxic-ischemic encephalopathy seen in survivors of perinatal asphyxia is a frequently encountered and a major clinical problem for which there is currently no effective treatment. Hematopoietic neuroprotective agents, such as erythropoietin (EPO) may rescue neurons from cell death in this setting. EPO is a cytokine hormone that has neuroprotective effect in vitro and in vivo. In this study, we evaluated the effect of posthypoxic EPO administration in an animal model of neonatal hypoxic-ischemic injury. Our results show that a single intracerebroventricular injection of EPO immediately after hypoxic-ischemic insult in neonatal rat model of hypoxic-ischemia reduced the extent of hypoxic-ischemic brain damage. The mean infarct volume assessed 7 days after hypoxia was significantly smaller in EPO-treated group than in the control group. These findings suggest that EPO may provide benefit after hypoxic-ischemic events in the developing brain, a major contributor to static encephalopathy and cerebral palsy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13129593     DOI: 10.1016/s0387-7604(03)00039-1

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  23 in total

1.  Improved cerebrovascular function and reduced histological damage with darbepoietin alfa administration after cortical impact injury in rats.

Authors:  Leela Cherian; J Clay Goodman; Claudia Robertson
Journal:  J Pharmacol Exp Ther       Date:  2011-01-26       Impact factor: 4.030

2.  Erythropoietin Treatment Exacerbates Moderate Injury after Hypoxia-Ischemia in Neonatal Superoxide Dismutase Transgenic Mice.

Authors:  R Ann Sheldon; Christine Windsor; Byong Sop Lee; Olatz Arteaga Cabeza; Donna M Ferriero
Journal:  Dev Neurosci       Date:  2017-04-27       Impact factor: 2.984

Review 3.  Epo and other hematopoietic factors.

Authors:  Sandra Juul; Ursula Felderhoff-Mueser
Journal:  Semin Fetal Neonatal Med       Date:  2007-02-23       Impact factor: 3.926

4.  Evaluation of the therapeutic benefit of delayed administration of erythropoietin following early hypoxic-ischemic injury in rodents.

Authors:  M L Alexander; C A Hill; T S Rosenkrantz; R H Fitch
Journal:  Dev Neurosci       Date:  2013-01-10       Impact factor: 2.984

5.  Erythropoietin: a multimodal neuroprotective agent.

Authors:  Nadiya Byts; Anna-Leena Sirén
Journal:  Exp Transl Stroke Med       Date:  2009-10-21

6.  Hypoxic ischemic brain injury: Potential therapeutic interventions for the future.

Authors:  Aaron J Muller; Jeremy D Marks
Journal:  Neoreviews       Date:  2014-05-01

7.  Differential short-term regional effects of early high dose erythropoietin on white matter in preterm lambs after mechanical ventilation.

Authors:  Samantha K Barton; Annie R A McDougall; Jacqueline M Melville; Timothy J M Moss; Valerie A Zahra; Tammy Lim; Kelly J Crossley; Graeme R Polglase; Mary Tolcos
Journal:  J Physiol       Date:  2015-10-08       Impact factor: 5.182

8.  Upregulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506).

Authors:  Keiko Oh-i; Hiroshi Keino; Hiroshi Goto; Naoyuki Yamakawa; Masaru Takeuchi; Masahiko Usui; Takuya Iwasaki
Journal:  Br J Ophthalmol       Date:  2007-10-16       Impact factor: 4.638

9.  Erythropoietin sustains cognitive function and brain volume after neonatal stroke.

Authors:  Fernando F Gonzalez; Regina Abel; C Robert Almli; Dezhi Mu; Michael Wendland; Donna M Ferriero
Journal:  Dev Neurosci       Date:  2009-08-11       Impact factor: 2.984

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.